Trials / Not Yet Recruiting
Not Yet RecruitingNCT07234474
A Phase I Study of YK012 in Primary Membranous Nephropathy
A Phase I Study of YK012, a Humanized CD19 × CD3 Bispecific Antibody, in Participants With Very High-Risk, Refractory Primary Membranous Nephropathy
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 66 (estimated)
- Sponsor
- Excyte Biopharma Ltd · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics(PK), pharmacodynamics (PD), immunogenicity, and preliminary efficacy of YK012 in participants with primary membranous nephropathy (pMN).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | YK012 | YK012 is a bispecific antibody targeting CD19 on B cells and CD3 on T cells leading to T cell-mediated cytotoxicity of malignant B cells |
Timeline
- Start date
- 2026-10-01
- Primary completion
- 2027-11-01
- Completion
- 2028-02-01
- First posted
- 2025-11-18
- Last updated
- 2026-02-05
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07234474. Inclusion in this directory is not an endorsement.